Chapter 20 of 25
- Define the target or biomarker
- Check evidence in this exact setting
- Confirm approval, access and monitoring
- Separate standard options from research
What you will learn
Understand antiangiogenic therapy and antibody-drug conjugates; know when molecular testing may help; distinguish established options from research.
Blocking blood-vessel signals
Bevacizumab blocks vascular endothelial growth factor, or VEGF, which helps tumours form blood vessels. It is used with chemotherapy in selected advanced cervical cancer settings. It is not a standard replacement for surgery or brachytherapy in curable early or locally advanced disease. Blood pressure, urine protein, bleeding, clotting, wound healing and bowel or urinary fistula risk require assessment.
Prior pelvic radiation and tumour involvement near hollow organs can make fistula particularly concerning. A fistula is an abnormal connection, for example between bowel or bladder and vagina. Report new leakage, unusual discharge, bleeding or severe pain. Planned surgery and dental or other procedures should be discussed with the team because timing around antiangiogenic treatment matters.
Antibody-drug conjugates
An antibody-drug conjugate, or ADC, links an antibody to a potent cell-killing payload. Tisotumab vedotin binds tissue factor and has evidence in previously treated recurrent or metastatic cervical cancer. Its cervical indication does not generally require routine tissue-factor selection. It is different from a checkpoint inhibitor, even though both use antibodies.
Eye toxicity is a distinctive risk. The treatment requires a prescribed eye-care protocol, assessments and precautions; eye pain, redness or vision changes need prompt reporting. Neuropathy and bleeding also matter. Do not borrow someone else's eye drops or assume routine lubricants replace the protocol. The randomized innovaTV 301 evidence and regional availability are discussed in the preceding chapter.
Molecular testing in selected advanced disease
Testing for mismatch-repair deficiency or microsatellite instability, tumour mutational burden and selected actionable alterations may open a tumour-agnostic treatment or trial in some jurisdictions. HER2 testing or broader profiling may be useful in selected advanced cases when a result could change care. Not every alteration is actionable, and an “actionable” laboratory label does not prove that a drug is approved, affordable or supported for this exact situation.
Ask whether tissue is adequate, whether a new biopsy is needed, what the test can realistically change and who will interpret the result. A negative panel does not mean that all treatments are ineffective. Liquid-biopsy findings and tissue findings may differ; a negative blood test can miss alterations. Germline findings have implications for relatives and need appropriate counselling, separate from routine tumour profiling.
Research and new strategies
Therapeutic HPV vaccines, cellular therapies, novel ADCs and combinations of immune or targeted medicines remain active research areas. A therapeutic vaccine aims to treat established disease and is different from routine preventive HPV vaccination. Promising early response rates do not prove longer survival or establish a standard treatment.
Clinical trials have eligibility rules, monitoring and consent processes. Ask about randomization, the comparison treatment, travel, costs, toxicity, access after the study and alternatives outside the trial. Registration on a trial database is not evidence that the treatment works. Avoid paid “immune boosting” packages or unregulated cell therapies presented as proven cures.
Misconception and common question
“A molecular match guarantees response” is false. Should everyone have a broad gene panel at diagnosis? Not necessarily; the usefulness depends on stage, histology and whether a result would change treatment now or guide a relevant trial.
Take-home messages
Ask what the drug targets and which evidence supports it. Confirm the exact local indication and monitoring. Separate preventive vaccines, therapeutic research and established cancer treatment.
References and review status
- FDA — Tisotumab vedotin regular approval, April 2024
- Tewari et al. GOG-240 final survival analysis, Lancet 2017
- NCI — Targeted cancer therapies
- NCI — Clinical trials information for patients
- Cibula et al. ESGO/ESTRO/ESP cervical cancer guidelines, 2023 update
Evidence/editorial check: 28 October 2026. AI-assisted preparation is separate from physician sign-off. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy